

| In € millions IFRS |
2010 | 2009 Pro forma |
2009 |
| Revenues | 226.3 | 186.1 | 101.9 |
| Gross margin | 132.1 | 103.2 | 68.5 |
| gross margin % | 58.4% | 55.5% | 67.2% |
| Operating income | 27.3 | 16.8 | 13.1 |
| operating margin % | 12.1% | 9.0% | 12.8% |
| Net cost of financial debt | (5.6) | (5.3) | (4.1) |
| Other income and financial charges | (0.7) | (0.2) | (0.5) |
| Net pre-tax profit | 21.1 | 11.3 | 8.4 |
| Tax expense | (6.2) | (3.3) | (1.9) |
| Income from companies, equity method | - | (1.2) | (1.2) |
| Net profit, Group share | 14.8 | 6.8 | 5.2 |
| Net profitability % | 6.5% | 3.7% | 5.1% |
| Average exchange rate for dollar ($) | 1.3220 | 1.3876 | 1.3876 |
2009 PF accounts include the Ingredients Division of the Natraceutical Group, consolidated as from January 1st, 2010
| In € m IFRS ASSETS |
31/12/10 | 31/12/09 | In € m IFRS LIABILITIES |
31/12/10 | 31/12/09 |
| Non-current assets | 189.4 | 164.0 | Shareholder equity | 168.8 | 144.8 |
| Non-current liabilities | 124.3 | 91.9 | |||
| Goodwill | 83.9 | 74.1 | Non-current financial debts | 108.4 | 82.8 |
| Intangible assets | 6.3 | 3.0 | Non-current provisions | 2.2 | 1.5 |
| Tangible assets | 92.3 | 83.7 | Deferred taxes | 11.2 | 7.6 |
| Financial assets | 0.7 | 1.4 | Derived instruments non-current liabilities | 2.5 | - |
| Deferred tax assets | 5.7 | 1.8 | |||
| Derived instruments non current assets | 0.5 | - | |||
| Current assets | 168.7 | 133.3 | Current liabilities | 65.0 | 61.4 |
| Inventory | 98.2 | 76.8 | Current provisions | 0.6 | 2.8 |
| Payable tax assets | 3.1 | 1.5 | Payable tax liabilities | 1.3 | 0.4 |
| Customers and other debtors | 49.6 | 39.4 | Suppliers and other creditors | 51.2 | 36.7 |
| Derived instruments current assets | 0.3 | - | Other financial liabilities | 9.9 | 16.3 |
| Cash and cash equivalent | 17.5 | 15.6 | Derived instruments current liabilities | 0.7 | - |
| Non-current assets held for sale | - | 0.8 | Bank advances | 1.3 | 5.2 |
| TOTAL ASSETS | 358.1 | 298.1 | TOTAL LIABILITIES | 358.1 | 298.1 |